5 EASY FACTS ABOUT AGO TUMOR DESCRIBED

In summary, during the last 10 years one of the most outstanding gain has been attained in HER2/neu-overexpressing MBC. Introduction of bevacizumab being a VEGF-directed targeted therapy continues to be a concern on discussion. Many of the novel therapeutics into the breast cancer armamentarium resulted in prolongation of survival for patients with